Reuters news agency reported on Friday that the US Food and Drug Administration (FDA), on 25 February 2021, approved storage and transportation of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
Reportedly, the companies had asked the US health regulator last week to relax requirements for their COVID-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers.
The director of the FDA's Centre for Biologics Evaluation and Research, Peter Marks, was quoted as saying: "Alternative temperature for transportation and storage will help ease the burden of procuring ultra-low cold storage equipment for vaccination sites and should help to get vaccine to more sites."
In December 2020, the US FDA had granted emergency use authorisation to the Pfizer-BioNTech vaccine and current label to be stored at temperatures between minus 80ºC and minus 60ºC, implying it has to be shipped in specially designed containers.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates